This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Conklin, K. A. Search for Related Content PubMed PubMed Citation Articles by Conklin, K. A. Social Bookmarking                         What's this?

Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity

Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, kconklin{at}mednet.ucla.edu

Preclinical and clinical studies suggest that anthracycline-induced cardiotoxicity can be prevented by administering coenzyme Q10 during cancer chemotherapy that includes drugs such as doxorubicin and daunorubicin. Studies further suggest that coenzyme Q10 does not interfere with the antineoplastic action of anthracyclines and might even enhance their anticancer effects. Preventing cardiotoxicity might allow for escalation of the anthracycline dose, which would further enhance the anticancer effects. Based on clinical investigation, although limited, a cumulative dose of doxorubicin of up to 900 mg/m², and possibly higher, can be administered safely during chemotherapy as long as coenzyme Q10 is administered concurrently. The etiology of the dose-limiting cardiomyopathy that is induced by anthracyclines can be explained by irreversible damage to heart cell mitochondria, which differ from mitochondria of other cells in that they possess a unique enzyme on the inner mitochondrial membrane. This enzyme reduces anthracyclines to their semiquinones, resulting in severe oxidative stress, disruption of mitochondrial energetics, and irreversible damage to mitochondrial DNA. Damage to mitochondrial DNA blocks the regenerative capability of the organelle and ultimately leads to apoptosis or necrosis of myocytes. Coenzyme Q10, an essential component of the electron transport system and a potent intracellular antioxidant, appears to prevent damage to the mitochondria of the heart, thus preventing the development of anthracycline-induced cardiomyopathy.

Key Words: anthracyclines • antioxidants • breast cancer • cancer • doxorubicin • cardiotoxicity • coenzyme Q10 • mitochondria

Integrative Cancer Therapies, Vol. 4, No. 2, 110-130 (2005)
DOI: 10.1177/1534735405276191


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Albini, G. Pennesi, F. Donatelli, R. Cammarota, S. De Flora, and D. M. Noonan Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention J Natl Cancer Inst, January 6, 2010; 102(1): 14 - 25. [Abstract] [Full Text] [PDF]

				K. Y. Wonders and B. S. Reigle Trastuzumab and Doxorubicin-Related Cardiotoxicity and the Cardioprotective Role of Exercise Integr Cancer Ther, March 1, 2009; 8(1): 17 - 21. [Abstract] [PDF]

				D. S. Hydock, C.-Y. Lien, and R. Hayward Anandamide Preserves Cardiac Function and Geometry in an Acute Doxorubicin Cardiotoxicity Rat Model Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2009; 14(1): 59 - 67. [Abstract] [PDF]

				G. Mantovani, C. Madeddu, C. Cadeddu, M. Dessi, A. Piras, E. Massa, R. Serpe, G. Antoni, and G. Mercuro Persistence, Up to 18 Months of Follow-Up, of Epirubicin-Induced Myocardial Dysfunction Detected Early by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, December 1, 2008; 13(12): 1296 - 1305. [Abstract] [Full Text] [PDF]

				B. D. Lawenda, K. M. Kelly, E. J. Ladas, S. M. Sagar, A. Vickers, and J. B. Blumberg Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy? J Natl Cancer Inst, June 4, 2008; 100(11): 773 - 783. [Abstract] [Full Text] [PDF]

				G. Mercuro, C. Cadeddu, A. Piras, M. Dessi, C. Madeddu, M. Deidda, R. Serpe, E. Massa, and G. Mantovani Early Epirubicin-Induced Myocardial Dysfunction Revealed by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers Oncologist, September 1, 2007; 12(9): 1124 - 1133. [Abstract] [Full Text] [PDF]

				S. A Shah, S. Sander, D. Cios, J. Lipeika, J. Kluger, and C M. White Electrocardiographic and Hemodynamic Effects of Coenzyme Q10 in Healthy Individuals: A Double-Blind, Randomized Controlled Trial Ann. Pharmacother., March 1, 2007; 41(3): 420 - 425. [Abstract] [Full Text] [PDF]

				R.-Y. Huang, D. Kowalski, H. Minderman, N. Gandhi, and E. S. Johnson Small Ubiquitin-Related Modifier Pathway Is a Major Determinant of Doxorubicin Cytotoxicity in Saccharomyces cerevisiae Cancer Res., January 15, 2007; 67(2): 765 - 772. [Abstract] [Full Text] [PDF]

				R. W. Moss Should Patients Undergoing Chemotherapy and Radiotherapy Be Prescribed Antioxidants? Integr Cancer Ther, March 1, 2006; 5(1): 63 - 82. [Abstract] [PDF]